Skip to main content
Figure 2 | Health and Quality of Life Outcomes

Figure 2

From: Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

Figure 2

Baseline to Week 12 endpoint changes in EORTC QLQ-C30 symptom scores. * For symptom scales, improvements are indicated by negative scores. ** p < 0.05 versus gp100 group. *** p > 0.05 for all comparisons (except for Constipation with p < 0.05). Mean change in scores were categorized as “no change” (0–5), “a little” (5–10 points), “moderate” (10–20 points), and “very much” (>20).

Back to article page